Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirtazapine for Agitation in Dementia (SYMBAD)
NCT03031184Phase 3Completed
- Sponsor
- University of Sussex
- Start
- Jan 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease (AD) comparing Mirtazapine with Placebo (2 arms). Primary endpoint: Cohen Mansfield Agitation Inventory at 12 weeks. Started Jan 2017; status: completed.
02
Drugs
mirtazapine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03031184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03031184.